Guideline for the management of clinically localized prostate cancer: 2007 update

[1] Middleton R.G., Thompson I.M., Austenfeld M.S., Cooner W.H., Correa R.J., Gibbons R.P., Et al., Prostate Cancer Clinical Guidelines Panel Summary report on the management of clinically localized prostate cancer, J Urol, 154, (1995)

[2] Thompson I.M., Goodman P.J., Tangen C.M., Lucia M.S., Miller G.J., Ford L.G., Et al., The influence of finasteride on the development of prostate cancer, N Engl J Med, 349, (2003)

[3] Petrylak D.P., Tangen C.M., Hussain M.H., Lara Jr. P.N., Jones J.A., Taplin M.E., Et al., Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer, N Engl J Med, 351, (2004)

[4] Tannock I.F., de Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N., Et al., Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer, N Engl J Med, 351, (2004)

[5] Aus G., Abrahamsson P.A., Ahlgren G., Hugosson J., Lundberg S., Schain M., Et al., Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial, Br J Urol Int, 90, (2002)

[6] Beckendorf V., Guerif S., Le Prise E., Cosset J.M., Lefloch O., Chauvet B., Et al., The GETUG 70 Gy vs. 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity, Int J Radiat Oncol Biol Phys, 60, (2004)

[7] Bill-Axelson A., Holmberg L., Ruutu M., Haggman M., Andersson S.O., Bratell S., Et al., Radical prostatectomy versus watchful waiting in early prostate cancer, N Engl J Med, 352, (2005)

[8] Bolla M., Collette L., Blank L., Warde P., Dubois J.B., Mirimanoff R.O., Et al., Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial, Lancet, 360, (2002)

[9] Bono A.V., Pagano F., Montironi R., Zattoni F., Manganelli A., Selvaggi F.P., Et al., Effect of complete androgen blockade on pathologic stage and resection margin status of prostate cancer: progress pathology report of the Italian PROSIT study, Urology, 57, (2001)

[10] Crook J., Ludgate C., Malone S., Lim J., Perry G., Eapen L., Et al., Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer, Int J Radiat Oncol Biol Phys, 60, (2004)

[1] Middleton R.G., Thompson I.M., Austenfeld M.S., Cooner W.H., Correa R.J., Gibbons R.P., Et al., Prostate Cancer Clinical Guidelines Panel Summary report on the management of clinically localized prostate cancer, J Urol, 154, (1995)

[2] Thompson I.M., Goodman P.J., Tangen C.M., Lucia M.S., Miller G.J., Ford L.G., Et al., The influence of finasteride on the development of prostate cancer, N Engl J Med, 349, (2003)

[3] Petrylak D.P., Tangen C.M., Hussain M.H., Lara Jr. P.N., Jones J.A., Taplin M.E., Et al., Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer, N Engl J Med, 351, (2004)

[4] Tannock I.F., de Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N., Et al., Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer, N Engl J Med, 351, (2004)

[5] Aus G., Abrahamsson P.A., Ahlgren G., Hugosson J., Lundberg S., Schain M., Et al., Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial, Br J Urol Int, 90, (2002)

[6] Beckendorf V., Guerif S., Le Prise E., Cosset J.M., Lefloch O., Chauvet B., Et al., The GETUG 70 Gy vs. 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity, Int J Radiat Oncol Biol Phys, 60, (2004)

[7] Bill-Axelson A., Holmberg L., Ruutu M., Haggman M., Andersson S.O., Bratell S., Et al., Radical prostatectomy versus watchful waiting in early prostate cancer, N Engl J Med, 352, (2005)

[8] Bolla M., Collette L., Blank L., Warde P., Dubois J.B., Mirimanoff R.O., Et al., Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial, Lancet, 360, (2002)

[9] Bono A.V., Pagano F., Montironi R., Zattoni F., Manganelli A., Selvaggi F.P., Et al., Effect of complete androgen blockade on pathologic stage and resection margin status of prostate cancer: progress pathology report of the Italian PROSIT study, Urology, 57, (2001)

[10] Crook J., Ludgate C., Malone S., Lim J., Perry G., Eapen L., Et al., Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer, Int J Radiat Oncol Biol Phys, 60, (2004)